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Tetrahydrobiopterin (BH4) is required for NO synthesis and inhibition of superoxide release from
endothelial NO synthase. Clinical trials using BH4 to treat endothelial dysfunction have produced mixed
results. Poor outcomes may be explained by the rapid systemic and cellular oxidation of BH4. One of the
oxidation products of BH4, 7,8-dihydrobiopterin (7,8-BH2), is recycled back to BH4 by dihydrofolate
reductase (DHFR). This enzyme is ubiquitously distributed and shows a wide range of activity depending
on species-speciﬁc factors and cell type. Information about the kinetics and efﬁciency of BH4 recycling in
human endothelial cells receiving BH4 treatment is lacking. To characterize this reaction, we applied a
novel multielectrode coulometric HPLC method that enabled the direct quantiﬁcation of 7,8-BH2 and
BH4, which is not possible with ﬂuorescence-based methodologies. We found that basal untreated BH4
and 7,8-BH2 concentrations in human endothelial cells (ECs) are lower than in bovine and murine
endothelioma cells. Treatment of human ECs with BH4 transiently increased intracellular BH4 while
accumulating the more stable 7,8-BH2. This was different from bovine or murine ECs, which resulted in
preferential BH4 increase. Using BH4 diastereomers, 6S-BH4 and 6R-BH4, the narrow contribution of
enzymatic DHFR recycling to total intracellular BH4 was demonstrated. Reduction of 7,8-BH2 to BH4
occurs at very slow rates in cells and needs supraphysiological levels of 7,8-BH2, indicating this reaction is
kinetically limited. Activity assays veriﬁed that human DHFR has very low afﬁnity for 7,8-BH2
(DHFoKm47,8-BH2) and folic acid inhibits 7,8-BH2 recycling. We conclude that low activity of
endothelial DHFR is an important factor limiting the beneﬁts of BH4 therapies, which may be further
aggravated by folate supplements.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. Tetrahydrobiopterin (BH4) is a cofactor of nitric oxide synthase
(NOS) that is required for nitric oxide (NO) production from
endothelial NOS (eNOS). This activity is explained by the unique
role of BH4 in the coupling of NADPH to L-arginine oxidation by
eNOS [1,2]. Decreasing BH4 enhances superoxide release from the
heme-oxygenase domain of eNOS (dimer) by a process known as
eNOS uncoupling [3,4]. Regulation of BH4 concentrations is
obtained either via de novo biosynthesis from GTP or the recycling
pathway using 7,8-dihydrobiopterin (7,8-BH2). This biosynthesis is
regulated by the concerted action of three enzymes, with GTP
cyclohydrolase I (GTPCH) catalyzing the ﬁrst committed step in the
reaction path. The recycling pathway is controlled by dihydrofolater Inc.
l.com (J. Vasquez-Vivar).
Open access under CC BYreductase (DHFR; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase,
EC 1.5.1.3), which catalyzes the reduction of 7,8-BH2 at the expense
of NADPH in various cell types [5,6]. Several studies have indicated
that both GTPCH and DHFR inﬂuence BH4 status in endothelial
cells, although their relative impacts and the role of DHFR in
supplementation regimes aimed at increasing intracellular BH4
have not been established in human endothelial cells.
DHFR is involved in essential cellular processes such as the
one-carbon pool pathway shuttling methyl groups required for the
de novo synthesis of purines, glycine, and dTMP in a coupled
reaction with thymidylate synthase using N5,N10-methylene tetra-
hydrofolate as substrate [7]. The product of the reaction, 7,8-
dihydrofolate (DHF), is reduced back to the methyl acceptor form,
tetrahydrofolate (THF), by DHFR. Generally, natural folates are
obtained from diet in the form of methyltetrahydrofolate. Another
source of THF and methylated analogs is folic acid (FA), a synthetic
form found in fortiﬁed food and dietary supplements. Folic acid
entry is conditional on its reduction to dihydrofolate and further license. 
J. Whitsett et al. / Free Radical Biology and Medicine 63 (2013) 143–150144reduction to THF by DHFR at rates that depend on organ- and
species-speciﬁc factors. The liver is the main organ regulating the
reduction of plasma synthetic folic acid concentrations, but human
liver DHFR catalyzes reduction at much slower rates than the rat
liver enzyme [8]. Its activity is regulated by protein expression,
which is controlled by DHFR protein binding to DHFR mRNA in the
coding region. Relieving this self-control is considered an impor-
tant aspect limiting methotrexate chemotherapeutic efﬁcacy and
increased resistance of human cancerous cells [9,10].
The complex mechanisms of DHFR regulation at the catalytic
and transcriptional levels and the tissue-speciﬁc variability are
important factors when considering the potential use of BH4 as a
therapeutic intervention to improve NO production from eNOS. It
has been suggested that DHFR assists in the maintenance and
increase of BH4 concentrations in the endothelium by recycling
7,8-dihydrobiopterin generated from oxidative degradation of BH4
[11–14]. Clinical studies using BH4 for the treatment of endothelial
dysfunction have rendered mixed results [15–19]. Promising
results have been indicated for the use of BH4 in the treatment
of vascular complications in sickle cell disease. Its application in
other vascular conditions such as hypertension has rendered less
than satisfactory results although the treatment is well tolerated
in human patients. To elucidate the inﬂuence of DHFR, we
examined the speciﬁc contribution of the DHFR-dependent path-
way to BH4 ﬂuctuations in human endothelial cells and of human
recombinant DHFR. Our results indicate that DHFR-dependent
recycling of BH4 via reduction of 7,8-BH2 is exceedingly slow,
limiting BH4 bioavailability. In addition, we report that folic acid, a
common ingredient of multivitamin therapies, may interfere with
DHFR’s capability to increase BH4 in endothelial cells.Experimental procedures
Chemicals
6R-Tetrahydrobiopterin (6R-BH4), 6S-tetrahydrobiopterin (6S-
BH4), 7,8-BH2, and methotrexate were from Schircks Laboratories
(Jona, Switzerland). Dithioerythritol (DTE), DHF, diethylenetriami-
nepentaacetic acid (DTPA), desferroxamine, folinic acid, folic acid,
and NADPH were from Sigma Chemical Co. (St. Louis, MO, USA).
Puromycin was from Invivogen (San Diego, CA, USA). Recombinant
human dihydrofolate reductase was from Novus Biologicals (Little-
town, CO, USA).
Plasmids
The RHS4533-NM_000791 vector was from the TRC-Hs1.0 short
hairpin RNA (shRNA) library distributed by Open Biosystems (Hunts-
ville, AL, USA). This vector contains a shRNA targeting the DHFR gene
expressed from the human U6 promoter and a puromycin-resistance
cassette expressed from the human phosphoglycerate kinase pro-
moter in the pLKO.1 plasmid background [20]. For simplicity we
designated this plasmid as pLKO.1-shDHFR. The second-generation
packaging plasmid psPAX2 and the envelope plasmid pMD2G con-
taining the vesicular stomatitis virus glycoprotein were obtained
through the laboratory of Dr. Didier Trono (Lausanne, Switzerland).
All plasmids were extracted and puriﬁed using the PureLink HiPure
Maxiprep plasmid preparation kit (Invitrogen, San Diego, CA, USA)
according to the manufacturer’s protocol.
Lentivirus production
One day before transfection exponentially growing 293T/17 cells
were seeded onto 100-mm culture dishes and incubated overnight
at 37 1C/5% CO2 in 10 ml of Dulbecco’s modiﬁed Eagle’s medium(DMEM), 10% fetal bovine serum (FBS), with penicillin and strepto-
mycin. The next morning the cells were at least 90% conﬂuent. One
hour before transfection, the cells were washed three times with
warm phosphate-buffered saline (PBS). The medium was replaced
with 5 ml of prewarmed Opti-MEM (Invitrogen) without FBS or
antibiotics and the cells were returned to the incubator. The cells
were cotransfected with a solution of 5 mg of psPAX2, 10 mg of
pLKO.1-shDHFR, 2 mg of pMD2G, and 30 ml of Lipofectamine 2000
(Invitrogen) mixed in Opti-MEM to a ﬁnal volume of 500 ml. Six
hours posttransfection, 5 ml of DMEM, 10% FBS, with penicillin and
streptomycin was added to the transfected cells. The next morning,
the culture medium was replaced with 10 ml of fresh DMEM, 10%
FBS, penicillin and streptomycin supplemented with 10 mmol/L
sodium butyrate. The cells were incubated for 48 h at 37 1C with
5% CO2 to allow for virus packaging and replication. All subsequent
handling of the culture media containing the virus particles was
done on ice. Transduction-ready lentivirus was harvested by cen-
trifugation of the culture medium at 4 1C and 550 g to remove cell
debris followed by sterilization through a 0.22-mm ﬁlter. The
ﬁltered virus solution was immediately aliquotted and stored at
−80 1C until the time of use.
Tetrahydrobiopterin and 7,8-dihydrobiopterin
Quantiﬁcation of 6R-BH4, 6S-BH4, and 7,8-BH2 was performed
by HPLC with electrochemical detection. Human aortic endothelial
cells (HAECs) were grown to conﬂuence in 100-mm dishes and
treated as described. Cells were washed twice with DPBS and
scraped into prechilled tubes. After being centrifuged for 5 min at
3000 rpm, pellets were syringe-lysed in 120 ml of 50 mM potas-
sium phosphate buffer, pH 2.6, with 1 mM DTE and 0.1 mM DTPA
freshly added. Lysates were spun at 13,000 rpm for 10 min.
Aliquots of 50 ml were separated using 50 mM potassium phos-
phate buffer, pH 2.6, on a Synergi Polar-RP column (Phenomenex,
Torrance, CA, USA) and analyzed using coulometric detection
(CoulArray ESA, Chelmsford, MA, USA) as described [21]. Standard
curves were constructed using authentic samples (10–250 nM).
Biopterin, isoxanthopterin, and pterin content in cell lysates was
analyzed by HPLC with ﬂuorescence detection (ex 340 nm; em
445 nm) using a C-18 Aqua column (Phenomenex) eluted with a
mixture of 98% triﬂuoroacetic acid (0.1%):2% acetonitrile. Concen-
trations were calculated using standards [22] and were normalized
to protein content.
Tissue isolation
Human adipose arterioles were obtained from discarded sub-
cutaneous and omental fat at the time of noncardiac surgery.
Arterioles were identiﬁed by microscopy and carefully cleaned of
fat before any testing. After harvest, arterioles were immediately
placed in cold Hepes buffer (in mM: 138 NaCl, 4 KCl, 1.2 MgSO4,
1.6 CaCl2, 1.2 KH2PO4, 0.026 EDTA, 6 glucose, 10 Hepes) and
transferred for analysis while fresh. De-identiﬁed information on
the donors was available (including age and history of coronary
artery disease, hypertension, diabetes, or high cholesterol). All
samples were obtained in accordance with a protocol approved by
the Medical College of Wisconsin’s Institutional Research Board.
Cell culture
HAECs and human umbilical vein endothelial cells (HUVECs)
were grown in endothelial cell growth medium supplemented
with 2% fetal bovine serum (Cell Applications, San Diego, CA, USA)
in 100-mm dishes. Conﬂuent cells (passages 3–7) were used.
Bovine endothelial (passages 3–7) and murine endothelioma
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bovine serum (Life Technologies, Gaithersburg, MD, USA).
DHFR knockout (DHFR−/−) HAECs
Cells were transduced with the lentivirus carrying the pLKO.1-
shDHFR construct. Five days after transduction, cells with the
stable integration of the transgene cassette were selected by
puromycin antibiotic resistance and supplemented with freshly
prepared 0.1 mmol/L folinic acid.
Recombinant human DHFR activity
Assays were performed by following NADPH oxidation at
340 nm and concentrations were calculated using an extinction
coefﬁcient of 6.22 mM−1 cm−1. Reactions were run at 25 1C and
assay buffer containing 25 mM 2-(N-morpholino)ethane sulfonic
acid, 50 mM tris(hydroxymethyl)aminomethane, 25 mM acetic
acid, 100 mM NaCl, and 5 mM dithiothreitol [23]. Enzyme activity
was measured with 7,8-dihydrofolate (0–100 mmol/L) and NADPH
(100 mmol/L). Alternative substrates were folate and 7,8-BH2
assayed under the same conditions. In cell homogenates control
assays for activity were performed with methotrexate 1 mM ﬁnal
concentration.
Nitric oxide measurements
HAECs were incubated with 5 mM DAF-2DA (4,5-diaminoﬂuor-
escein diacetate) in culture medium. After 30 min, vascular
endothelial growth factor (VEGF; 20 ng/ml) was added to stimu-
late NO production for an additional 30 min. After, cells were
washed twice, pelleted, and syringe-lysed in phosphate buffer
(10 mM, pH 7.5) with 100 mM DTPA and 0.1% Triton X-100. An
aliquot was taken for protein determination and the remaining
lysate loaded onto a Centricon (10,000 molecular weight cutoff).
After centrifugation for 1 h at 10,000 rpm at 4 1C, the eluent (50 ml)
was loaded onto a Synergi fusion column eluted with potassium
phosphate buffer (pH 7.5, 10 mM):5% v/v acetonitrile. Authentic
DAF-2 T was used as a standard for quantiﬁcation using ﬂuores-
cence detection at 490 nm excitation and 515 nm emission. Values
were normalized to protein content in the sample.
Statistical analysis
Data are plotted as means7SD. Data plotting and statistical
analysis (ANOVA) were performed using Origin software
(OriginLab, Northampton, MA, USA). A p value of o0.05 was
considered statistically signiﬁcant compared to controls.0.0
0.2
VEGF-NS 10 100 +L-NAME
D
A
F
BH4 (µM)
Fig. 1. (A) Endothelial cell species-speciﬁc differences in basal BH4 and 7,8-BH2
concentrations. Growing HAECs, HUVECs, BAECs, and sEnd.1 cells ∼70% conﬂuent
were directly collected in BH4 assay buffer (50 mM phosphate buffer, pH 2.6,
containing 1 mM freshly added DTE) after being rinsed with PBS. Cells and human
arterioles were homogenized on ice and cleared of cellular debris by centrifugation.
The supernatant was clariﬁed using Centricon ﬁlters (10,000 Da exclusion) and
samples were immediately analyzed for BH4 and BH2 using HPLC with electro-
chemical detection with authentic standards. Results represent the means7SD,
n≥4 samples, except human tissue represents the average of tissue collected from
two donors. (B) Dose-dependent BH4 effects on eNOS activity. HAECs were
pretreated or not with L-NAME (L-NG-nitroarginine methyl ester) (0.1 mM) for
30 min and/or BH4 for 1 h before stimulation with VEGF (20 ng/ml) for 30 min as
described under Experimental procedures. †po0.05 vs VEGF untreated (VEGF-NS),
‡po0.05 vs BH4 treatment without L-NAME.Results
Species-speciﬁc variations in endogenous levels of endothelial BH4
and 7,8-BH2
Endothelial BH4 and 7,8-BH2 levels reported in the literature
show a wide range of concentrations [24–26]. To test whether the
variation is explained by species-speciﬁc differences or the use of
different methodologies, we analyzed BH4 and 7,8-BH2 in
untreated human (HAEC) and bovine endothelial cells (BAECs)
and also a transformed mouse endothelial cell line (sEnd.1) and
freshly isolated human arterioles using a multielectrode electro-
chemical detection (ECD)–HPLC method [21]. Unlike ﬂuorescence
methodologies, the multielectrode coulometric detection enables
the direct measurement of both BH4 and 7,8-BH2 (or BH2) in the
same injection of cell extract at applied potentials of ≥280 mV for7,8-BH2 and ≤150 mV for BH4 detection. We found that in HAECs,
basal BH4 concentrations were close to the limit of electrochemical
detection (0.3070.07 pmol/mg protein), whereas 7,8-BH2 was
higher (2.6171.09 pmol/mg protein) (Fig. 1). A similar proﬁle
was found in freshly isolated human vessels from healthy donors
with no increased risk for developing cardiovascular disease (i.e.,
hypertension, hypercholesterolemia, diabetes) and in HUVECs. In
contrast, BH4 concentrations in BAECs and sEnd.1 cells were higher
than those of 7,8-BH2 and in close agreement with values in the
literature [26,27]. Because BAECs and sEnd.1 cells used the same
culture medium, we conclude that differences cannot be ascribed
to the use of different methodologies or culture conditions. There-
fore, the wide-ranging concentrations most probably reﬂect
species-speciﬁc differences in BH4 metabolism. The low BH4
concentrations and BH4:7,8-BH2 ratio found in HAECs and HUVECs
agree with previous reports, which explained the differences as a
conditional response to lack of laminar shear-mediated activation
by phosphorylation of GTPCH [24]. The ﬁnding of similar BH4
levels in freshly isolated healthy human arterioles that had been
under constant blood ﬂow stimulation indicates that BH4 levels
are intrinsically low.
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Fig. 2. Dose- and time-dependent effects of BH4 treatment in human endothelial
cells. Treatments were performed in low-passage (3 or 4) growing HAECs in culture
medium supplemented with desferroxamine for 1 h before addition of (A) BH4 (1,
10, and 100 mM) for an additional hour. (B) Same as (A) but cells were collected
after 2 h treatment. (C) HAECs were treated with BH4 (10 mM) and analyzed at 0.5,
1, and 2 h posttreatment. Before collection, the cells were rinsed to avoid
contamination from the medium. Values represent the means7SD, n≥4 experi-
ments. †po0.02 vs basal BH4; *po0.001 vs basal 7,8-BH2.
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The intracellular BH4 levels in HAECs and HUVECs correlated
with NO-producing activity in these cells. Treatment of HAECs
with BH4 increased NO activity although not proportionally to
treatment doses (Fig. 1B). Maximal NO-production rates were
stimulated with 10 mM BH4, whereas the effect of 100 mM BH4
was less prominent. This indicates that eNOS had reached max-
imal saturation with 10 mM BH4 or that BH4 does not proportion-
ally accumulate in HAECs with increasing doses.
Dose-dependent responses in cellular BH4 and 7,8-BH2 after BH4
treatment of HAECs
To estimate the dose-dependent effects of BH4 treatment,
HAECs were treated with increasing concentrations of freshly
prepared BH4 for 1 h. As shown in Fig. 2A there was an increase
of ∼10-fold in intracellular BH4 (from 0.3570.05 to 5.571.4 pmol/
mg protein) with treatments of 10 mM BH4, or ∼14 nmol BH4/mg
protein when dose is normalized for cell protein. Assuming the
increase is linear in time, we estimated that intracellular changes
in BH4 represented only 0.4% of the treatment dose. When
considering BH4 and 7,8-BH2 together, this proportion increased
to ∼1% of the initial treatment dose. Higher BH4 doses led to a
proportional increase in intracellular BH4 although the estimated
change in intracellular BH4 corresponds to ∼1% of initial treatment
dose. This effect was not improved by pre- or cotreatment of cells
with either ascorbate or N-acetylcysteine or both. All the incuba-
tions were performed with an iron chelator, desferroxamine,
which stabilizes BH4 in the medium (Table 1). The effects of
incubation time were estimated by treating cells with the same
initial doses of 10 and 100 mM BH4 for 2 h. In this case, both BH4
and 7,8-BH2 concentrations were signiﬁcantly lower than those of
the previous 1-h incubation time (Fig. 2B), indicating that BH4 and
7,8-BH2 are unstable in the cellular milieu. To better characterize
the time-dependent effects of BH4 treatment, HAECs were treated
with 10 mM BH4 and analyzed every 30 min for up to 2 h. This
analysis conﬁrmed that BH4 levels peak early and rapidly return to
basal levels. The 7,8-BH2 levels also peak early but remain higher
than basal levels after 2 h, suggesting that its reduction back to
BH4 is slow. We conclude that endothelial cells respond to BH4
supplementation with a rapid and transient change followed by
accumulation of 7,8-BH2. The accumulation of 7,8-BH2, however,
was not as prominent as predicted from BH4 loss, suggesting the
formation of other BH4-degradation products. The formation of
other non-electrochemically active products was examined by
HPLC with ﬂuorescence detection. Both biopterin and pterin were
identiﬁed in the direct analysis of cell lysates without further
reaction with oxidizing reagents. Together biopterin and pterin
totaled 2.5 pmol/mg protein after 1 h treatment. Together these
ﬁndings conﬁrm that BH4 is unstable under physiologically rele-
vant conditions, with generation of several products including 7,8-
BH2 [6,28].
BH4 uptake versus recycling
The changes in BH4 in the previous experiments did not
elucidate the possibility that 7,8-BH2 reduction by DHFR contri-
butes to early increasing BH4. Thus to distinguish between direct
BH4 uptake and DHFR-catalyzed recycling of 7,8-BH2 to cellular
BH4, the natural 6R-BH4 (or BH4) and its synthetic nonnatural 6S-
diastereomer (6S-BH4) were used. Both 6R-BH4 and 6S-BH4 when
oxidized to 7,8-BH2 lose their chirality, thus they are similarly
reduced by DHFR to generate BH4 (Fig. 3A) [29]. Because 6S- and
6R-BH4 can be separated by HPLC with electrochemical detection
(Fig. 3B) their differential increase can be established. Treatment ofHAECs with 10 or 100 mM 6S-BH4 for 1 h revealed that cellular 6S-
BH4 reached signiﬁcantly higher concentrations than BH4 (Fig. 3C),
indicating that 6S-BH4 is directly taken up by cells and that the
contribution of 7,8-BH2 recycling to BH4 is marginal. In this
scenario, recycling of 7,8-BH2 would have increased 6R-BH4 (BH4
in the ﬁgure) but this is not the case. The changes in 6S-BH4 and
7,8-BH2 at 1 h in cells treated with 10 mM 6S-BH4 showed the same
trend seen in previous experiments when using 10 mM BH4
(Fig. 2D). Greater than 70% of 6S-BH4 was lost between 1 and
2 h posttreatment, followed by even higher accumulation of 7,8-
BH2 with negligible changes in BH4. After 12 h, BH4 was increased
Table 1
Stabilization of BH4 in culture medium with desferroxamine.
Amount BH4 added: 1 mM 10 mM 100 mM
BH4 (mM) 7,8-BH2 (mM) BH4 (mM) 7,8-BH2 (mM) BH4 (mM) 7,8-BH2 (mM)
Culture medium 0.0170.010 0.0570.02 0.0970.021 0.9470.21 0.6470.56 11.3870.50
+Desferroxamine 0.187001* 0.0470.02 4.5570.22** 0.9370.14 25.9672.71** 19.9172.62
BH4 was freshly added to the cell culture and aliquots were collected 1 h after incubation at 37 1C and immediately combined with preservation solution (0.1 M potassium
phosphate buffer, pH 2.6, with freshly added 2 mM DTE and 0.2 mM DTPA). BH4 was analyzed by HPLC with electrochemical detection. Cells were treated or not with
desferroxamine (0.1 mM) for 1 h before BH4 treatment in the same medium. Values are means7SEM (n¼4)
n po0.05 versus no desferroxamine.
nn po0.01 versus no desferroxamine.
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Fig. 3. Real-time assessment of the DHFR-dependent BH4 recycling in HAECs treated with 6S-BH4 diastereomer. (A) 6S-BH4 (synthetic nonnatural analog) and 6R-BH4
(natural analog) oxidation produces 7,8-BH2 that can regenerate 6R-BH4 via DHFR-dependent reduction. (B) A typical ECD–HPLC elution proﬁle of 6R-BH4, 6S-BH4, and 7,8-
BH2 standards used for quantiﬁcation. HAECs were treated with (C) 10 mM 6S-BH4 and (D) 100 mM 6S-BH4 for the indicated times. Cell extracts were analyzed by ECD–HPLC
and values normalized for protein content. Results represent the means7SD of n≥4 experiments. †po0.001 vs basal BH4; *po0.001 vs basal 7,8-BH2; n≥5 experiments.
J. Whitsett et al. / Free Radical Biology and Medicine 63 (2013) 143–150 147from 0.3 to only ∼0.7 pmol/mg protein. This trend was also veriﬁed
by treatments with 100 mM 6S-BH4, in which intracellular BH4
levels reached only 1.5 pmol/mg protein after 12 h (Fig. 3D). Taken
together these results indicate that increases in intracellular BH4
after treatment reﬂect direct uptake of the cofactor, a process that
accounts for only the acute increase in cellular concentrations.
Reduction of 7,8-BH2 to BH4 accounts for late effects, which occur
at exceedingly slow rates.
DHFR-dependent recycling of 7,8-BH2 to BH4 in HAECs
Analysis of the expression levels of enzymes in the BH4 path-
way in HAECs showed a robust signal for DHFR, indicating the
potential to recycle 7,8-BH2 (Fig. 4). To better characterize the
enzymatic activity, HAECs were treated with 10 mM 7,8-BH2, which
leads to an increase of 430-fold above basal 7,8-BH2 levels in 2 h
(Fig. 4C) with a disproportionally small BH4 increase. After 12 h
incubation, 7,8-BH2 reached an even higher level and BH4 also
slowly increased. Together these data show that 7,8-BH2 is readily
taken up by HAECs and that its reduction by DHFR is slow despite
the high concentration of 7,8-BH2. To conﬁrm the role of DHFR in
this reaction, we generated an HAEC line with deﬁcient expression
of the enzyme using shRNA methodology. Suppressive activity ofthe shRNA transfection was conﬁrmed by Western blots showing
that the transformed cell line (DHFR−/−) expressed ∼83% less
protein than wild type (Fig. 4B). Also DHFR−/− growth was
dependent on freshly added folinic acid (leucovorin), which allows
for some purine and pyrimidine synthesis to occur under condi-
tions of reduced dihydrofolate reductase activity [30]. When the
DHFR−/− cells were treated with 10 mM 7,8-BH2, the intracellular
7,8-BH2 reached higher concentrations than in wild-type cells
after 2 h, although the two cell types accumulated similar amounts
after 12 h incubation (Fig. 4D). Importantly, these cells did not
increase BH4, demonstrating that DHFR is rate limiting in BH4
production from 7,8-BH2. These experiments also demonstrated
that 7,8-BH2 is relatively stable in the cellular milieu, representing
∼1.2% of treatment dose during the ﬁrst 2 h.
Kinetic assays of human DHFR
Enzyme activity assays using puriﬁed human DHFR demon-
strated that 7,8-BH2 stimulates lower enzyme activity than DHF,
the natural substrate of the enzyme. Generally, the kcat of DHFR
varies with DHF c 7,8-BH24folic acid (Table 2). The estimated
kcat using DHF was in agreement with reported values in the
literature of ∼12 s−1 [31–34]. Previous studies by others established
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Fig. 4. 7,8-Dihydrobiopterin reduction to BH4 depends on dihydrofolate reductase in human endothelial cells. (A) RT-PCR analysis of BH4 synthetic enzymes in HAECs. GCH,
GTP cyclohydrolase I; DHPR, dihydropteridine reductase; SR, sepiapterin reductase. (B) Western blot analysis showing reduced DHFR protein levels in DHFR-knockout HAECs
(DHFR−/−) compared to wild type. Rat liver extracts were used as a positive marker for DHFR, and β-actin was used as protein loading control. Intracellular changes in BH4
were assessed in (C) wild-type and (D) DHFR−/− cells upon supplementation with 10 mM 7,8-BH2 for 2 and 12 h. Values represent the means7SD of n≥5 experiments.
†po0.001 vs basal BH4; *po0.001 vs basal 7,8-BH2; ‡po0.05 vs DHFR−/− 7,8-BH2.
Table 2
Steady-state parameters for human dihydrofolate reductase.
Substrate kcata (s−1) Kmb (μM) KDc (μM) Interaction rated
(μM−1 s−1)
DHF 18.370.1e,f 0.1570.01e,f — 122e,f
DHF 12.570.2g 0.1070.03g 0.15h —
DHF 1172i 0.1270.02i 0.1270.04g 190728h
7,8-BH2 6.270.1 28.170.5 3175g 0.4470.01h
Folic acid 0.5f 0.88j 0.08370.00g 0.003070.0005h
Human DHFR activity was assayed in MATS buffer (25 mM Mes, 25 mM acetate,
50 mM Tris, 100 mM sodium chloride) supplemented with freshly added 5 mM DTT
at 25 1C with 100 mM NADPH and the indicated substrate. The enzyme was
preincubated with NADPH before addition of substrate and its consumption was
followed at 340 nm. Values represent the means7SD.
a Turnover number.
b Michaelis constant.
c Kinetic dissociation constant.
d Values determined from V/KEt.
e Recombinant human DHFR.
f This work.
g Ref. [28].
h Ref. [29].
i Ref. [30].
j
J. Whitsett et al. / Free Radical Biology and Medicine 63 (2013) 143–150148that 7,8-BH2 is an alternate DHFR substrate but its afﬁnity to the
enzyme is weak. Studies using ﬂuorescence titration of residue
Phe31 in the active site of human DHFR estimated that binding and
dissociation constants (kon, koff) of 7,8-BH2 favored dissociation of
the substrate. This could explain the need for large amounts of 7,8-
BH2 to stimulate DHFR activity [28]. In contrast, folate has a higher
binding (kon) but stimulates only a fraction of the activity (Table 2)
[31,33]. Activity assays of human liver DHFR using folic acid as
substrate have estimated a speciﬁc enzyme activity of 0.02 nmol
tetrahydrofolate/min/g wet wt tissue, whereas an activity of
26.1 nmol tetrahydrofolate/min/g wet wt tissue is found with
dihydrofolate as substrate [29]. The inﬂuence of 7,8-BH2 and FA
in human endothelial DHFR activity was assessed by following
methotrexate-inhibitable dihydrofolate-stimulated NADPH con-
sumption in cell homogenates. HAEC homogenates consumed
NADPH at a rate of ∼0.65 nmol/min/mg protein with no measur-
able activity in DHFR−/− homogenates. Cell extracts from HAECs
treated with 7,8-BH2 (10 mmol/L,12 h) increased methotrexate-
inhibitable NADPH consumption with respect to untreated cells
by 30%. Addition of FA to cell homogenates led to an ∼10%
inhibition in enzyme activity. The DHFR−/− cells did not increase
NADPH consumption in any of the treatments.Ref. [31].Effects of folic acid on endothelial 7,8-BH2 reduction
Because the effects of FA on the reduction of 7,8-BH2 to BH4
may be controlled by concentration, we examined the effects of FA
(0.1–5.0 mM) pretreatment on 7,8-BH2 recycling to BH4. In this case
DHFR-dependent reduction of 7,8-BH2 was decreased and this
effect was saturated at ∼1.0 mM FA with an average inhibition of
25% (Fig. 5). Because FA is activated to DHF, it is possible that FA
inhibits BH4 production by a simple competitive mechanism
decreasing available DHFR.Discussion
The main ﬁnding of this work is that recycling of BH4 via the
DHFR pathway in human endothelial cells is exceedingly slow,
indicating that this pathway has a minor role in the maintenance
of endothelial BH4 levels. This fact may signiﬁcantly inﬂuence the
success of BH4 treatments in which systemic and cellular 7,8-BH2
can increase severalfold.
Our observation that BH4 concentrations in human endothelial
and umbilical vein cells and freshly isolated arterioles are very low
is in agreement with previous reports using human umbilical cells,
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Fig. 5. Folic acid inhibits BH4 production from 7,8-BH2 in HAECs. Cells were treated
with freshly prepared folic acid (FA; 5.0 mM for 2 h) in the culture medium. After
the culture medium was replaced, 7,8-BH2 was added and cells were incubated for
12 h at the indicated concentrations. *Bonferroni-corrected p¼0.0083 vs no FA.
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line EAhy926 [24–27]. This ﬁnding may be explained by the slow
rate of biosynthesis or recycling of BH4 in human cells. Because
inhibition of BH4 biosynthesis rapidly causes a state of BH4
deﬁciency in isolated blood vessels [35], it has been concluded
that BH4 is rapidly lost under normal conditions and that constant
biosynthesis is necessary to satisfy cellular cofactor needs. Also
implicit in this conclusion is the possibility that 7,8-BH2 recycling
is not a good source of BH4 in endothelial cells. The oxidative
metabolism of BH4 generates quininoid–BH2 (qBH2), 7,8-BH2,
pterin-radical intermediates, isoxanthopterin, and biopterin
[36,37]. Until now, the speciﬁc endothelial biochemical mechan-
isms controlling the formation and fate of these products have not
been well deﬁned. A well-known reaction of BH4 is with iron and
iron-containing proteins such as cytochrome c [38]. Because iron–
proteins are abundant, it is possible that in a cellular context, BH4
is constantly oxidized as a consequence of its interactions with
iron-containing centers. The product of this reaction is a radical
species that undergoes a number of reactions including dismuta-
tion to generate 7,8-BH2 and BH4 or reaction with oxygen to
generate hydrogen peroxide and qBH2. Therefore 7,8-BH2 is
unlikely to be the only and speciﬁc product of BH4 oxidation and
is yet to be proven as a good marker of BH4 degradation as
discussed in the literature. The importance of 7,8-BH2 as an
oxidation product may lie in the fact that it can be recycled back
to BH4 via DHFR. The characteristics of this reaction are, however,
highly dependent on the cell type in human tissues.
We found that 7,8-BH2 in endothelial cells and freshly isolated
human arterioles is present in higher concentrations than BH4. The
high proportion of 7,8-BH2 is intriguing because it is believed that
in endothelial cells 7,8-BH2 is rapidly recycled to BH4 via DHFR
[12,14]. Also, the relatively high 7,8-BH2 levels in HAECs are in
direct contrast to ﬁndings in BAECs or sEnd.1 cells, where a higher
BH4:7,8-BH2 ratio is typical under basal conditions [11–14,25].Thus understanding species-speciﬁc features of BH4 metabolism
in human cells is even more important.
We found that in HAECs treated with BH4 doses comparable to
those of therapeutic regimens (5–20 mg BH4/kg wt) [17–19], 7,8-
BH2 is the predominant species. Only in the treatments with high
doses and for very short times was BH4 increased. Using diaster-
eomers, 6R-BH4 and 6S-BH4, we demonstrated that the direct
uptake of BH4 better explains the acute increase in intracellular
BH4 and that DHFR recycling of 7,8-BH2 is marginal. This unex-
pected result was better characterized by using 7,8-BH2 that
showed a slow conversion to BH4.
Pharmacokinetic studies have shown that oral administration
of 20 mg/kg BH4 in healthy adult subjects rapidly increased total
plasma biopterin (i.e., the sum of biopterin, BH2, and BH4 con-
centrations), reaching Cmax of 0.4 mM within ∼2.5 h with an
estimated bioavailability (AUC0–10 h) of 3.6 mM, representing
∼3.5% of the initial total dose of 1800 mg for an individual
weighing 90 kg [39]. Total plasma biopterin in coronary artery
disease patients supplemented with 400–700 mg of BH4 reached
o0.07 mM and even lower levels of 7,8-BH2, ∼0.03 mM [40].
Although it is not known whether these values represent Cmax,
they illustrate that 7,8-BH2 represents only a small fraction of the
initial treatment dose and is unlikely to signiﬁcantly stimulate
DHFR-mediated conversion to BH4. The physiological signiﬁcance
of these changes is yet to be established. Previously we showed
that 7,8-BH2 competes for the BH4-binding site on eNOS and
inhibits NO formation to increase superoxide release by encoura-
ging a futile NADPH-oxidation cycle [4]. The NO-forming activity
is, however, more sensitive to inhibition by 7,8-BH2 than
uncoupled superoxide formation [4]. Thus the relatively high 7,8-
BH2 to BH4 accumulated in endothelial cells upon supplementa-
tion predicts that supplementation may decrease eNOS activity. By
following NO-forming activity (DAF assay), we found that 100 mM
BH4 stimulated less NO production than 10 mM BH4 despite the
fact that intracellular 7,8-BH2 was higher than BH4. This indicates
that regulation of eNOS by intracellular BH4 and BH2 in endothelial
cells is inﬂuenced by cofactor concentrations and perhaps by the
accessibility of 7,8-BH2 to the eNOS binding site.
Dihydrofolate reductase can accept alternative substrates such
as folic acid and 7,8-BH2 in addition to its natural substrate
dihydrofolate. However, the rate of reduction of 7,8-BH2 is slower
as veriﬁed by measuring NADPH oxidation, tetrahydrofolate, and
BH4 [29,41]. Similarly we found that 7,8-BH2 is a better substrate
for DHFR than folic acid but a poor substrate compared to DHF.
These differences may be relevant when considering potential
competitive reactions in the cellular milieu. Folic acid therapy is
common, and high doses can be found in vitamin supplements
and fortiﬁed foods. Here, we showed that folic acid at concentra-
tions 1/100 and less of that found in vitamin supplements
inhibited DHF and 7,8-BH2 reduction by human DHFR in vitro,
and it reduced the conversion of 7,8-BH2 to BH4 in HAECs. This
effect seems to be a general phenomenon because addition of folic
acid also inhibited DHFR activity in sEnd.1 murine endothelioma
cells, which compares with a 27% inhibition caused by methotrex-
ate under similar experimental conditions. This information may
be important in the design of the therapeutic use of BH4 in
cardiovascular conditions because most patients generally receive
vitamin supplements.
Regulation of BH4 metabolism in human endothelial cells is
complex and not well understood. It remains unclear why human
endothelial cells maintain low BH4 despite the presence of
enzymes able to generate BH4 via de novo and salvage pathways
and its critical regulatory role in eNOS activity. In several cell types
DHFR assumes an active role in regulating BH4. Here we showed
that enzyme activity of DHFR in human endothelial cells is low,
which may be a factor explaining low basal BH4 in human cells
J. Whitsett et al. / Free Radical Biology and Medicine 63 (2013) 143–150150under physiological conditions. Importantly, the low DHFR activity
in endothelial cells seems to be a limitation in the use of BH4 for
the treatment of endothelial dysfunction associated with several
cardiovascular conditions.Acknowledgment
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